Imunon, Inc. IMNN
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Imunon, Inc. (IMNN) is a healthcare company listed in the US with a market value of about $4M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -131%.
About Imunon
Imunon is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $500000 in 2017 to $500000 in 2022, growth of about 0.0% a year. It was profitable in 0 of the last 10 years in our data. Its share count fell by 70% over three years (buybacks).
Score: 0.4 / 5
Checks passed
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $500000 | $500000 | $500000 | $500000 | $500000 | $500000 | — |
| Net income | -$14M | -$19M | -$20M | -$36M | -$21M | -$21M | -$17M | -$12M | -$20M | -$22M |
| Free cash flow | -$14M | -$19M | -$19M | -$23M | -$17M | -$16M | -$21M | -$7M | -$17M | -$18M |
| EPS (diluted) | $-2.28 | $-5.65 | $-0.72 | $-1.68 | $-1.28 | $-3.36 | $-3.85 | $-3.40 | $-13.60 | $-59.45 |
| Net margin | — | — | — | -7179.6% | -4153.9% | -4296.7% | -3370.3% | -2376.7% | -4080.4% | — |
| ROIC | -143.4% | -280.8% | -131.5% | -67.1% | -31.6% | -68.6% | -71.7% | -35.5% | -54.6% | -174.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $15.20, 2317% above the current price; targets range from $6.00 to $25.00; the consensus rating is “Strong buy”; expected EPS is $-2.58 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Imunon pay a dividend?
Not currently.
Is Imunon a good stock to buy?
We do not give buy or sell advice. Imunon scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.